Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
Novartis is moving to make radioligand therapy (RLT) a core pillar of its oncology strategy in Japan, leveraging the launch of Pluvicto (lutetium vipivotide tetraxetan (177Lu)) to expand indications, build out treatment infrastructure, and position the country for additional RLT…
To read the full story
Related Article
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…